New updates have been reported about Brainomix.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Brainomix has launched its Brainomix 360 Stroke Next Generation platform at the International Stroke Conference, positioning the company to deepen its role in acute stroke decision-support across global markets. The upgraded platform adds a first-in-market, regulatory-cleared net water uptake feature using standard non-contrast CT scans, providing automated, percentage-based quantification of early brain injury to guide treatment and transfer decisions.
The new release also emphasizes workflow and usability, with enhanced DICOM viewing and AI-driven, patient-specific insights, and has already secured a Red Dot Design Award for excellence in safety, usability, and innovation, underscoring its competitive differentiation. At the same conference, Brainomix is presenting five studies on Brainomix 360 Stroke, including work showing that large-scale adoption could improve thrombolysis and thrombectomy rates, deliver better functional outcomes, increase long-term quality of life, and generate a net monetary benefit for health systems.
Additional research from Brainomix validates its imaging foundation model for automating follow-up infarct volume segmentation, assesses prospective performance of Brainomix 360 Triage LVO, analyzes the impact of collateral circulation dynamics during inter-hospital transfer, and explores new methods to detect stroke mimics. Three of these abstracts have received the American Heart Association’s Paul Dudley White International Scholar Award, reinforcing the firm’s academic credibility and the robustness of its evidence base.
Chief Medical and Innovation Officer Dr. George Harston highlighted that the automated net water uptake metric complements existing ischemic core volume and e-ASPECTS outputs, providing deeper insight into severe stroke injury from routine CT and potentially increasing clinician confidence where uncertainty currently limits access to effective therapies. For executives and investors, the combination of regulatory-cleared innovation, design recognition, and economic and clinical validation signals a strengthening competitive position for Brainomix in AI-enabled stroke imaging, with clear pathways to wider adoption across hospital networks and international markets.